MediciNova (NASDAQ:MNOV) Given Buy Rating at D. Boral Capital

D. Boral Capital reiterated their buy rating on shares of MediciNova (NASDAQ:MNOV) in a research note issued to investors on Friday,Benzinga reports. D. Boral Capital currently has a $9.00 price target on the biopharmaceutical company’s stock.

A number of other equities research analysts have also recently weighed in on MNOV. Lucid Cap Mkts upgraded shares of MediciNova to a “strong-buy” rating in a report on Monday, January 5th. Weiss Ratings reissued a “sell (d-)” rating on shares of MediciNova in a research report on Monday, December 29th. Two analysts have rated the stock with a Strong Buy rating, one has issued a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $7.00.

MediciNova Stock Down 1.7%

Shares of MNOV stock opened at $1.72 on Friday. The business’s fifty day moving average is $1.50 and its 200 day moving average is $1.38. The stock has a market cap of $84.54 million, a price-to-earnings ratio of -6.88 and a beta of 0.52. MediciNova has a twelve month low of $1.13 and a twelve month high of $2.06.

MediciNova (NASDAQ:MNOV) last announced its earnings results on Wednesday, November 12th. The biopharmaceutical company reported ($0.06) EPS for the quarter, beating analysts’ consensus estimates of ($0.08) by $0.02. The business had revenue of $0.12 million for the quarter. Equities research analysts expect that MediciNova will post -0.24 earnings per share for the current fiscal year.

Institutional Investors Weigh In On MediciNova

An institutional investor recently bought a new position in MediciNova stock. Citadel Advisors LLC acquired a new position in MediciNova, Inc. (NASDAQ:MNOV) in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund acquired 72,897 shares of the biopharmaceutical company’s stock, valued at approximately $92,000. Citadel Advisors LLC owned about 0.15% of MediciNova as of its most recent SEC filing. Hedge funds and other institutional investors own 9.90% of the company’s stock.

MediciNova Company Profile

MediciNova, Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel small-molecule therapeutics for neurodegenerative, inflammatory, fibrotic and oncological diseases. Founded in the late 1990s, the company advances its proprietary compounds through clinical trials and strategic partnerships, with a goal of addressing areas of high unmet medical need. MediciNova is headquartered in San Diego, California, and maintains a presence in Tokyo to support collaborations and regulatory interactions in Asian markets.

The company’s leading clinical asset, MN-166 (ibudilast), is an anti-inflammatory and neuroprotective agent originally approved in Japan for asthma and post-stroke dizziness.